Related Experiment Videos
Antithrombotic agents for acute coronary syndromes
1Gill Heart Institute, Division of Cardiovascular Medicine, University of Kentucky, 900 S. Limestone Street, 326 Wethington Building, Lexington, KY 40536-0200, USA. Mukherjee@uky.edu
Summary
Low-molecular-weight heparins (LMWHs) are effective alternatives to unfractionated heparin (UFH) for acute coronary syndromes (ACS), offering similar safety profiles. Newer agents like fondaparinux and bivalirudin show promise with reduced bleeding risks.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis Management
Background:
- Antithrombotic agents are crucial in managing acute coronary syndromes (ACS).
- Unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs) are commonly used, with LMWHs showing potential benefits in specific ACS patient groups.
Purpose of the Study:
- To review the current evidence on the efficacy and safety of antithrombotic agents in acute coronary syndromes (ACS).
- To compare the effectiveness and bleeding risks of various antithrombotic therapies, including heparins, fondaparinux, and bivalirudin.
Main Methods:
- Systematic review of clinical trial data.
- Analysis of efficacy and safety outcomes for different antithrombotic agents in ACS patients.
Main Results:
- LMWHs demonstrate comparable efficacy to UFH in acute myocardial infarction and unstable angina/non-ST-segment elevation myocardial infarction, with no increased major bleeding risk.
- Newer agents like fondaparinux and bivalirudin exhibit similar efficacy to heparins but with a notable reduction in bleeding complications.
- While LMWHs can be more expensive than UFH, their clinical benefits and the safety profile of newer agents warrant consideration.
Conclusions:
- Antithrombotic agents play a vital role in ACS management.
- LMWHs and newer agents offer effective therapeutic options with varying cost and bleeding profiles, guiding clinical decision-making.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:30Acute Coronary Syndrome III: Diagnostic Studies
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...